This nonrandomized phase 2 trial examines remission after combination therapy with ibrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia.
See more from Akiva Diamond
Phase II single arm data of frontline Ibrutinib and venetoclax in older or high risk patients with CLL. Patients had either del(17p), TP53-mutated, del(11q), unmutated IgVH, or age 65 years or older. 75% of patients achieved marrow uMRD as best response. Estimated 3 year PFS was 93%.